Biologics for the treatment of noninfectious uveitis
Author:
- 1 May 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 30 (3) , 138-150
Abstract
There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with ongoing evaluation for efficacy in uveitis; and therapeutics for which investigation for efficacy in NIU is warranted. The tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab has recently gained approval by the Food and Drug Administration for the treatment of noninfectious intermediate, posterior, and panuveitis. There is mounting evidence supporting the use of tocilizumab and rituximab in NIU. There is developing interest in evaluating the interleukin (IL)-23 inhibitors for efficacy in NIU. The TNF-α inhibitors adalimumab and infliximab have the greatest body of data supporting their use in NIU. These agents are considered second-line therapy for most forms of NIU but may be considered first-line therapy for uveitis associated with Behçet's disease and juvenile idiopathic arthritis. The B-cell inhibitor rituximab and the IL-6 inhibitor tocilizumab also have documented efficacy in NIU. Tocilizumab and interferon therapy may be particularly efficacious in the management of uveitic macular edema. The IL-23 inhibitors and janus kinase inhibitors are agents whose efficacy in NIU will likely be determined in the near future.Keywords
This publication has 131 references indexed in Scilit:
- Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical TrialsOphthalmology, 2013
- Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment TrialOphthalmology, 2011
- Cyclosporine for Ocular Inflammatory DiseasesOphthalmology, 2010
- Mycophenolate Mofetil for Ocular InflammationAmerican Journal of Ophthalmology, 2010
- Cyclophosphamide for Ocular Inflammatory DiseasesOphthalmology, 2010
- Methotrexate for Ocular Inflammatory DiseasesOphthalmology, 2009
- Azathioprine for Ocular Inflammatory DiseasesAmerican Journal of Ophthalmology, 2009
- High-dose Daclizumab for the Treatment of Juvenile Idiopathic Arthritis–Associated Active Anterior UveitisAmerican Journal of Ophthalmology, 2009
- High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitisJournal of Autoimmunity, 2008
- TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1Nature Medicine, 2007